Neuropace Inc (NPCE)

$NPCE I miss you from the bottom of my heart. But you are also responsible for this situation, too. I haven’t heard anything from your side for too long. Please make something different so that i can believe you really care for our relationship. P.S: Did i say that i miss -us- very much?

$NPCE Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum building.

$NPCE Drug resistant Epilepsy check! Focal and generalized Epilepsy in the not so distant future. Be patient with $NPCE as it’s the early innings.

AlphaBriefing’s deep dive into quantum sensors in living cells and BCIs also features $NPCE (Neuropace). An interesting angle for neurotech investors. Read the article: https://www.alphabriefing.com/quantum-sensors-inside-living-cells-the-next-frontier-for-brain-computer-interfaces/

$NPCE Purely antidote but my son has not had a seizure since his Feb surgery with RNS and his wife comments on his improved memory, both goals for the surgery. Given good earnings, margins, forecasts and upcoming study results this should be higher but multiple factors.

$NPCE will FDA knock them?

$NPCE @RocketThief You already pulled the trigger?

Wells Fargo has adjusted their stance on NeuroPace ( $NPCE ), setting the rating to Overweight with a target price of 17 → 15.

$NPCE NeuroPace reports Q2 EPS (26c), consensus (22c) -- Q2 revenue $23.52M, consensus $23.08M. -- Raises FY25 revenue view to $94M-$98M from $93M-$97M, consensus $94.78M. -- On track to submit Nautilus data to FDA in 2H

"Heads up alert! Upcoming earnings on Tuesday, 8/12/2025 for $NPCE Bullish (7.8) ### Financial Analysis NeuroPace, Inc. (NASDAQ: NPCE) is demonstrating considerable momentum in the medical technology sector, particularly in the niche of epilepsy management with its neurostimulator devices. The company's strategic response to the Centers for Medicare & Medicaid Services (CMS) decision to maintain the current reimbursement structure is crucial, as it ensures consistent revenue streams from its primary product offerings. As NeuroPace approaches its financial results announcement for the second quarter of 2025, expectations are centered around continued revenue growth and operational efficiency improvements under the new CFO, Patrick F. Williams. The company's P/E ratio, while not directly stated, is expected to reflect its rapid growth phase, potentially higher than industry averages due to the strategic market position and innovation-driven portfolio. NeuroPace's EPS growth is anticipated to be robust, aligning with the broader trend of increasing adoption of neurostimulator technology. Revenue forecasts are optimistic, bolstered by the maintained CMS reimbursement strategy, which is expected to drive both top-line growth and market confidence. Compared to industry peers such as AngioDynamics (ANGO), NeuroPace's focus on niche markets and specialized technology provides a competitive edge, although it also subjects the company to specific regulatory and market risks. ### Upcoming Earnings Report NeuroPace is scheduled to release its second-quarter 2025 financial results on August 12. Historically, the company has shown a pattern of steady financial improvement, and analyst consensus estimates suggest a continuation of this trend. The upcoming report is expected to highlight revenue growth and potential EPS improvements, driven by strategic decisions and operational refinements. Analyst consensus is cautiously optimistic, predicting that the company's recent management changes and strategic focus will positively impact the stock. The potential impact on the stock will largely depend on whether the company meets or exceeds these expectations, with a significant beat likely to further enhance investor sentiment. ### Sector Performance NeuroPace operates within the broader medical technology sector, which has been experiencing robust growth driven by innovation and increased healthcare spending. The sector's performance is marked by a strong demand for cutting-edge medical devices and technologies, particularly those addressing chronic conditions like epilepsy. Companies within this sector are benefiting from favorable regulatory environments and advancements in healthcare technology. NeuroPace, with its specialized focus, is well-positioned to capitalize on these trends, though it remains crucial for the company to navigate the regulatory landscape effectively to maintain its growth trajectory. - Funds were net buyers of $NPCE during the previous reporting quarter. - Funds with large holdings in $NPCE include: - OrbiMed Advisors LLC, MV: $42MM. Fund Rank: 55% www.orbimed.com - Soleus Capital , MV: $32MM. Fund Rank: 54% - First Light Asset Management LLC, MV: $19MM. New position. Fund Rank: 55% www.firstlightam.com - Armistice Capital LLC, MV: $14MM. Fund Rank: 72% www.armisticecapital.com - Deerfield Management Co, MV: $6MM. New position. Fund Rank: 90% www.deerfield.com - Last 10 days performance: -3% - Last 30 days performance: -16% - Last 90 days performance: -28% Some of the latest news articles: - Title: Orthofix (OFIX) Q2 Earnings and Revenues Beat Estimates Publication Date: 8/5/2025 12:25:03 PM, Source: yahoo URL: https://finance.yahoo.com/news/orthofix-ofix-q2-earnings-revenues-122503319.html?.tsrc=rss - Title: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases Publication Date: 8/1/2025 11:30:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-commends-cms-maintaining-fy25-113000625.html?.tsrc=rss - Title: NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 Publication Date: 7/29/2025 8:05:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/neuropace-report-second-quarter-2025-200500610.html?.tsrc=rss - Title: AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates Publication Date: 7/15/2025 11:40:02 AM, Source: yahoo URL: https://finance.yahoo.com/news/angiodynamics-ango-reports-q4-loss-114002208.html?.tsrc=rss Follow us on stocktwits.com and Substack (chessgmstocks.substack.com). Not a financial advice. Not a trading signal."